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Abstract
Background:  Epithelial ovarian cancer is a devastating disease associated with low survival
prognosis mainly because of the lack of early detection markers and the asymptomatic nature of
the cancer until late stage. Using two complementary proteomics approaches, a differential protein
expression profile was carried out between low and highly transformed epithelial ovarian cancer
cell lines which realistically mimic the phenotypic changes observed during evolution of a tumour
metastasis. This investigation was aimed at a better understanding of the molecular mechanisms
underlying differentiation, proliferation and neoplastic progression of ovarian cancer.
Results: The quantitative profiling of epithelial ovarian cancer model cell lines TOV-81D and TOV-
112D generated using iTRAQ analysis and two-dimensional electrophoresis coupled to liquid
chromatography tandem mass spectrometry revealed some proteins with altered expression
levels. Several of these proteins have been the object of interest in cancer research but others were
unrecognized as differentially expressed in a context of ovarian cancer. Among these, series of
proteins involved in transcriptional activity, cellular metabolism, cell adhesion or motility and
cytoskeleton organization were identified, suggesting their possible role in the emergence of
oncogenic pathways leading to aggressive cellular behavior.
Conclusion:  The differential protein expression profile generated by the two proteomics
approaches combined to complementary characterizations studies will open the way to more
exhaustive and systematic representation of the disease and will provide valuable information that
may be helpful to uncover the molecular mechanisms related to epithelial ovarian cancer.
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Background
Despite years of research in clinical aspects of ovarian can-
cer, this gynaecological pathology is still one of the most
deadly cancers among women in most western countries.
The search for biomarkers to detect early phase ovarian
cancer and to monitor disease progression has been tar-
geted for a long time by the medical community. DNA
microarray expression profiling-based research was
applied to identify candidate genes that may account for
tumorigenesis as well as proteomics-based search for spe-
cific protein biomarkers that could facilitate the detection
of ovarian cancer. However, few quantitative systematic
analysis of ovarian cancer by proteomics approaches have
been undertaken. Recently, we reported a proteome pro-
filing of the TOV-112D cell line, a human model for the
study of epithelial ovarian cancer [1]. To go further in the
comprehension of ovarian carcinogenesis, we have inves-
tigated the differential protein expression profile between
low malignant potential and highly proliferative human
epithelial ovarian cancer cell lines TOV-81D and TOV-
112D. These cell lines are spontaneously immortalized
epithelial ovarian cancer cell lines derived from ovarian
malignant tumours [2]. The growth characteristics and
tumorigenic potential of these cell lines parallel the prog-
nosis of the patients from which these cell lines are
derived. The TOV-112D cell line comes from an extremely
aggressive ovarian endometrioid tumor (grade 3) while
the TOV-81D originates from an intermediate grade
(grade 1–2) but a clinically rather indolent papillary
serous adenocarcinoma. The TOV-81D cell line has been
the subject of several microarray-based analysis that
revealed a high similarity to normal ovarian surface epi-
thelium [3-5], a distinctive feature that suggests that it is
an excellent baseline for comparisons. Ovarian cancers are
characterized by extensive molecular alterations and com-
plex chromosomal aberrations. However, normal ovarian
surface epithelium and TOV-81D cell line display few
chromosomal differences, an additional feature that
makes this cell line a good model in a differential profile
framework [2]. The morphology of TOV-81D cells is
highly similar to the morphology of normal ovarian epi-
thelium, in opposition to TOV-112D cells that are smaller
and more refractile, a characteristic of highly transformed
cell lines. TOV-112D provides several useful advantages
for our specific study. In particular, it rates amongst the
most aggressive EOC cell lines and has the added advan-
tage that it was derived from a chemotherapy naïve
patient, a condition that minimize genetic alterations
often associated with adjuvant therapy such as chemo-
therapy or radiation therapy [2] and thus it might be
argued that is more closely recapitulates the fundamental
molecular changes associated with ovarian cancer.
Although the histopathology of these two cell lines may
appear diverse, there is a growing body of literature that
suggests that both from a molecular [6] and pathological
(reviewed in Gilks, 2004 [7]) point of view that it is
doubtful whether there is a consistently recognizable set
of high-grade endometrioid carcinomas that differ in any
substantive way from high-grade papillary serous carcino-
mas. Both TOV-81D and TOV-112D have been exten-
sively characterized at a genomic and transcriptomic
levels and therefore make this model particularly attrac-
tive from a systems biology point of view [3-5,8-10]. Tak-
ing into account all the pertinent characteristics of these
cell lines supports the notion that the differential protein
expression analysis of TOV-81D and TOV-112D cell lines
provides an attractive model to assess molecular events
associated with EOC.
Two quantitative proteomics approaches were selected for
comparing TOV-81D and TOV-112D proteomics profiles:
isobaric tags for relative and absolute quantitation
(iTRAQ) analysis and two-dimensional electrophoresis
(2DE) coupled to liquid chromatography tandem mass
spectrometry (LC MS/MS). The first approach is a gel free
mass spectrometry technique that uses isobaric amine
specific tags to compare the peptide intensities between
samples and infer quantitative values for corresponding
proteins. The second approach is based on the differential
two-dimensional gel electrophoresis pattern between pro-
tein samples. This alternative approach gives addition bio-
logical information such as isoelectric point drift or
molecular weight alterations from which we can suggest
important implications to protein functions. Both meth-
ods generate quantitative data that provide a differential
protein dataset when a protein expression ratio between
TOV-81D and TOV-112D cell lines is applied. These com-
plementary technologies [11] reinforces the identification
of distinctive protein expression between TOV-81D and
TOV-112D and provide a reliable tool to estimate relevant
protein changes in the context of human ovarian cancer.
This study is dedicated to explore the proteome's molecu-
lar alterations associated with ovarian cancer, providing
helpful information that could be used in conjuction with
complememtary approaches such as gene expression pro-
filing to have a more inclusive and global view of the dis-
ease.
Results and discussion
Comparative iTRAQ™ protein expression analysis 
between TOV-81D and TOV-112D epithelial ovarian 
cancer model cell lines
The Gene Ontology classification of differentially expressed proteins 
reveals a clusterizing of proteins
The quantitative evaluation of protein expression profiles
between low and high malignancy ovarian cancer cell
lines was performed using the iTRAQ technology which
infer relative protein abundance from MS analysis [12].
The threshold for potentially significant change in protein
expression has been statistically determined using Stat-Proteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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graphics Centurion's (version 15.1.03, StatPoint, Hern-
don, VA) generalized logistic distribution to the ratios
(TOV112D/TOV81D) computed for all the iTRAQ identi-
fied proteins [see Additional file-1]. At a p-value of 0.10
(90% confidence), ratios above 2.5 and under 0.59 are
significantly different from the average to be considered as
a potential change in protein expression. At a p-value of
0.05, these values are 3.0 and 0.41. Values at 90% confi-
dence were used as a cut-off in this study [see Additional
file-2] although ratios at 95% confidence should be kept
in mind for more confident change in protein expression.
The most prominent protein expression changes are listed
in Table 1 as 37 differentially expressed proteins that meet
the 95% confidence threshold criteria. A biological proc-
ess clustering of these proteins based on the Gene Ontol-
ogy (GO) Consortium [13] annotations was created in
order to perceive the distribution of the differentially
expressed proteins within important cellular regulatory
functions (Figure 1). Proteomics studies generate large
amounts of data that needs to be structured for easier
interpretation and evaluation of biological relevance.
Ontologies provide such structured description of biolog-
ical information that can be further analyzed into clusters
of functionally related proteins. In the present study,
rather than following the distribution trend associated
with all the iTRAQ identifications, over- and underex-
pressed proteins are enriched in specific GO categories.
Notably, proteins involved in cytosqueleton organization,
cell motility and adhesion are over-representated relative
to their proportion in the overall protein population (Fig-
ure 1A). This concept has been extended by assessing sta-
tistical overrepresentation of specific GO categories using
BiNGO, a tool developped to highlight predominant
functional themes in a dataset and to visualize them as an
integrated molecular interaction network. (Figure 1B).
Differentially expressed proteins in the context of ovarian cancer
Several proteins identified in this study with strong iTRAQ
differential expression ratios were previously studied in
association with human ovarian cancer or other epithelial
disorders, an indication that this study is actually address-
ing targets of interest. For example, The IGF II mRNA-
binding protein 1 (formely Coding region determinant-
binding protein (CRD-BP/IMP1)) which is characterized
with the highest iTRAQ protein ratio have been proposed
as a prognostic marker for patients with ovarian [14] and
colon cancer [15]. This protein stabilizes the c-Myc pro-
toncogene mRNA regions of instability which results in
the protection of the messenger from endonucleolytic
attack and thereby prolongs the mRNA half-life [16]. The
levels of c-Myc protein has been linked to cell prolifera-
tion, differentiation and neoplastic transformation [17].
Another example is the high mobility group protein
HMGI-C, also featuring a high differential expression
ratio. HMG proteins are a family of architectural transcrip-
tion factors establishing transcriptionaly active or inactive
chromatin domains [18]. The HMGI-C gene is probably
one of the most commonly rearranged gene in malignant
tumours [19] so its identification as a highly overex-
pressed protein in TOV-112D is not surprising. The
expression of high mobility group proteins have been
evaluated in ovarian carcinomas and characterized as a
frequent feature of ovarian cancer [20-22]. The latter pro-
teins are interacting selectively with nucleic acid but other
proteins involved in the metabolism of nucleic acid are
also strongly enhanced in the TOV-112D protein expres-
sion profile compared to TOV-81D. One of these is the
elongation factor 1-alpha 2 (eEF1A-2). It has been shown
to be an oncogenic factor likely associated with the devel-
opment of ovarian cancer [23] and also have been identi-
fied as a useful diagnostic marker and therapeutic target
for a high proportion of breast tumours [24].
Differential gene expression analysis have been per-
formed to understand the biochemical and molecular
changes involved in the formation and progression of
ovarian tumors. Notably, the most prominent overex-
pressed gene identified between advanced and local ovar-
ian adenocarcinoma is collagen alpha 1(III) chain
precursor (COL3A1) a gene which corresponding protein
have been shown by our iTRAQ analysis to be overex-
pressed in TOV-112D. Interestingly, the product of the
COL3A1 gene have been found to increase the degree of
malignancy in serous ovarian carcinoma [25].
On the other hand, underexpressed proteins characterized
with low iTRAQ ratio such as the transgelins were also
described as important factors in early events involved in
tumor progression and have been proposed as diagnostic
markers for epithelial breast [26] and colon cancer
[26,27]. The down regulation of transgelins in malignant
cells is observed in various carcinomas including ovarian
epithelial cancer [28]. Another example is thrombospon-
din-1 which as emerged as a protein with reduced expres-
sion in TOV-112D. Thrombospondin-1 is an angiogenesis
inhibitor [29,30] that as been implicated in tumor growth
and progression [31]. The reduction of thrombospondin
expression has been suggested to result in the develop-
ment of a pro-angiogenic environment and malignant
phenotype in epithelial ovarian carcinoma [32]. The
thrombospondin gene has also been identified as an
underexpressed gene in a comparative gene expression
analysis between three-dimensional epithelial ovarian
cancer cultures and monolayers, an indication of poten-
tially altered angiogenic signaling resulting from the reor-
ganisation of matrix proteins and cell-surface receptors to
which thrombospondin-1 interacts at the extracellular
matrix [33].P
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Table 1: iTRAQ analysis of differentially expressed proteins between human epithelial ovarian cancer cell lines TOV-112D and TOV-81D†.
Accession Entrez Gene GO Gene SwissProt Description Number of 
unique peptides
Protein ratio (112D/
81D)
%RSD Validation
IPI00008557 10642 RNA metabolism/protein biosynthesis IGF2BP1 Q9NZI8 Insulin-like growth factor 2 mRNA-binding protein 1 2 11,9 81
IPI00005996 8091 Transcription HMGA2 P52926 High mobility group protein HMGI-C 2 8,1 100
IPI00218914 216 Response to stress ALDH1A1 P00352 Aldehyde dehydrogenase 1A1 6 5,8 43 2D
IPI00021033 1281 Cell adhesion COL3A1 P02461 Collagen alpha-1(III) chain precursor 4 5,0 79 2D
IPI00014424 1917 Protein biosynthesis EEF1A2 Q05639 Elongation factor 1-alpha 2 3 4,2 80 2D
IPI00028376 1678 Transport/protein metabolism TIMM8A O60220 Mitochondrial import inner membrane translocase subunit Tim8A 2 4,2 14
IPI00030131 7112 Cytoskeleton organizationanisation TMPO P42167 Lamina-associated polypeptide 2, isoforms beta/gamma 3 3,8 21
IPI00329745 10128 RNA metabolism LRPPRC P42704 130 kDa leucine-rich protein 3 3,8 30
IPI00301189 51477 Lipid biosynthesis ISYNA1 Q9NPH2 Myo-inositol 1-phosphate synthase A1 2 3,7 23
IPI00165467 10643 RNA metabolism/protein biosynthesis IGF2BP3 O00425 Insulin-like growth factor 2 mRNA-binding protein 3 3 3,3 50
IPI00292387 9221 RNA metabolism NOLC1 Q14978 Nucleolar phosphoprotein p130 2 3,3 22
IPI00218493 3251 Puridine salvage HPRT1 P00492 Hypoxanthine-guanine phosphoribosyltransferase 2 3,1 15
IPI00218918 301 Membranes binding/cell motility ANXA1 P04083 Annexin A1 7 3,0 41 2D&WB
IPI00216044 22913 RNA metabolism RALY Q9UKM9 RNA-binding protein Raly 2 3,0 18
IPI00000105 9961 Response to stress MVP Q14764 Major vault protein 3 0,40 87
IPI00455315 302 Membranes binding/cell motility ANXA2 P07355 Annexin A2 3 0,40 33
IPI00477536 2317 Cell motility/Cytoskeleton 
organization/signal transduction
FLNB Q60FE7 Filamin B 2 0,38 47
IPI00333541 2316 Cell motility/Cytoskeleton 
organization/signal transduction
FLNA P21333 Filamin-A 10 0,36 46
IPI00296099 7057 Cell motility/cell adhesion THBS1 P07996 Thrombospondin-1 precursor 2 0,35 67
IPI00013808 81 Cell motility/cell adhesion ACTN4 O43707 Alpha-actinin-4 2 0,33 22
IPI00029111 1809 Pyrimidine metabolism DPYSL3 Q6DEN2 Dihydropyrimidinase-like 3 protein (DPYSL3 protein) 4 0,30 85 2D
IPI00554788 3875 Cytoskeleton organizationanisation KRT18 P05783 Keratin-18 2 0,29 19
IPI00306604 3678 Cell adhesion ITGA5 P08648 Integrin alpha-5 precursor 2 0,29 45
IPI00163187 6624 Cytoskeleton organization/cell 
motility
FSCN1 Q16658 Fascin 2 0,24 18 2D
IPI00031008 3371 Cell adhesion TNC P24821 Tenascin-C 2 0,23 71
IPI00182373 8974 Collagen biosynthesis P4HA2 O15460 Prolyl 4-hydroxylase subunit alpha-2 precursor 5 0,22 22 2D
IPI00472165 5352 Collagen biosynthesis PLOD2 O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 precursor; 3 0,21 55 2D
IPI00550363 8407 Cytoskeleton organization/cell 
motility
TAGLN2 P37802 Transgelin-2 2 0,20 11 2D&WB
IPI00216138 6876 Cytoskeleton organization/cell 
motility
TAGLN Q01995 Transgelin 5 0,20 58
IPI00008494 3383 Cell adhesion ICAM1 P05362 Intercellular adhesion molecule 1 precursor (ICAM1) 4 0,17 35
IPI00216135 7168 Cell motility/cell adhesion TPM1 P09493 Tropomyosin alpha-1 chain 2 0,16 38 2D
IPI00007118 5054 Cell adhesion/motility/urokinase 
regulation
SERPINE1 P05121 Plasminogen activator inhibitor 1 precursor (PAI-1) 2 0,15 27 2D
IPI00414283 2335 Cell motility/cell adhesion FN1 P02751 Fibronectin precursor 2 0,11 8
IPI00026663 220 Response to stress ALDH1A3 P47895 Aldehyde dehydrogenase 1A3 3 0,11 39 2D
IPI00442073 1465 Cell motility CSRP1 P21291 Cysteine and glycine-rich protein 1 3 0,08 255
IPI00297646 1277 Cell adhesion COL1A1 P02452 Collagen alpha-1(I) chain precursor 5 0,08 50
IPI00178352 2318 Cell motility/Cytoskeleton 
organization/signal transduction
FLNC Q14315 Filamin-C 3 0,07 39
†Selected protein expression ratios were confirmed by western blot (WB) analysis. Differentially expressed proteins also identified by comparative two-dimensional electrophoresis are indicated (2D). %RSD = (standard deviation/mean) × 
100Proteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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Distribution of the proteins identified by iTRAQ analysis according to Gene Ontology (GO) categories Figure 1
Distribution of the proteins identified by iTRAQ analysis according to Gene Ontology (GO) categories. (A) Relative distribu-
tion of proteins in selected GO terms for proteins that meet the under- or overexpression threshold for iTRAQ ratios 
between TOV-81D and TOV-112D cell lines compared to the overall protein identifications. (B) BiNGO determination of sta-
tistically overrepresented GO categories for the differentially expressed proteins between TOV-81D and TOV-112D cell lines. 
The biological network subgraph has been visualized using Cytoscape software.Proteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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Theses differentially expressed proteins were recognized
in differential expression analysis and further investigated
for their relationship with disease mechanisms. We
believe that other targets revealed by the present study
could provide usefull information for studies on ovarian
cancer.
Downregulation of TOV-112D proteins involved in cell adhesion, 
motility and cytoskeleton organization
Rearrangement of extracellular membrane proteins and
cytoskeletal microfilaments induce major cellular mor-
phological alterations in transformed cells. The action of
cross-linking proteins is particularly important to potenti-
ate the invasiveness of tumor cells. The differential expres-
sion of some membrane-associated proteins and proteins
that could be associated with cytoskeletal organization
was expected given the pronounced morphological differ-
ences between TOV-112D and TOV81D (Figure 2) and
their different growth characteristics. TOV-81D cells are
unable to grow without solid support while TOV-112D
cells formed large dense cell foci in semisolid medium [2].
Moreover, the injection of TOV-112D cell-line in nude
mice result in the rapid appearance of tumours while no
tumours are seen after the injection of TOV-81D cell line.
A significant part of these differential growth characteris-
tics are likely to be the consequence of changes in plasma
membrane properties and dynamics. The identification of
the extracellular matrix component collagen alpha 1 is
particularly relevant since it is not only involved in struc-
tural support of tissues but could also exhibit modulatory
effect on malignant cell behaviour [34]. Besides, the diver-
gent growth features between the two cell lines could also
be explained by different processing of extra cellular stim-
uli. The TOV-112D overexpressed protein myo-inositol 1-
phosphate synthetase-1 is likely involved in the synthesis
of inositol phospholipids, a component of plasma mem-
brane that convey extracellular signals from a variety of
peptide signalling molecules into cells [35].
In opposition to proteins whose abundance is increased
in TOV-112D cells, proteins identified with biological
functions in association with cytosqueleton organization
are characterized with relatively low TOV112D:TOV81D
ratios, an indication of underexpression pattern. A good
exemple is the identification of the cysteine and glycine-
rich protein 1 (CSRP1) which is one of the most underex-
pressed protein relative to iTRAQ differential expression
analysis ratios. Recently, a zebra fish homolog of CSRP1
have been shown to control cell morphology and other
dynamic cell behaviors [36]. It is conceivable that the loss
of CSRP1 could play a role in the remodeling of TOV-
112D cytosqueleton.
In addition, the iTRAQ comparative proteome analysis
underscores the underexpression of a cluster of actin-
binding proteins that are involved in integrin-mediated
biological responses. Actually, Filamin A/B/C, Talin,
Alpha-actinin1/4, Fascin and Integrin alpha-5 could all be
involved in the integrin family of cell adhesion molecules
pathways [37-39]. The underexpression of important
molecules involved in extracellular matrix adhesion is
consistent with the behaviour of TOV-112D cells which
produces tumours rapidly, an indication of high mobility
and invasion power.
Changes at the plasma membrane are also underscored by
the drastic underexpression of cellular matrix and cell
adhesion proteins such as fibronectin, intergrin or the
intercellular adhesion molecule-1 (ICAM-1). These pro-
teins participate to cellular migration and invasion behav-
iour. Since TOV-112D are not only highly proliferative
but also easily disseminates compared to TOV-81D cells,
the downregulation of proteins involved in cell adhesion
support the idea of modified extracellular matrix compo-
sition that could afford for the different dissemination
potential observed between the two cell lines. The plas-
minogen activator inhibitor-1 precursors (PAI-1) also
have functions in line with the idea of differential biolog-
ical behaviour based on plasma membrane phenotypes.
PAI-1 downregulates the plasminogen activator that
degrades a range of extracellular basement membrane
components [40]. Since the expression of the major plas-
minogen inhibitor is dramatically reduced in TOV-112D
cell lines, it is tempting to speculate that overactivation of
extracellular membrane remodelling contributes to the
metastatic capacity of this highly proliferative cell line.
However, this result contrasts with mRNA expression
analysis of PAI-1 in epithelial ovarian cancer where PAI-1
mRNA levels where shown to be elevated [41], in opposi-
tion to protein quantitation using iTRAQ comparative
analysis.
Morphological aspect of the TOV cell lines as observed  under a phase contrast microscope Figure 2
Morphological aspect of the TOV cell lines as observed 
under a phase contrast microscope. TOV-81D cells show a 
flat morphology similar to normal ovarian epithelium (A) 
while TOV-112D cells show a highly rounded morphology 
characteristic of highly transformed cell lines (B) as already 
published [2].Proteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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Table 2: Comparative protein expression analysis of TOV-81D and TOV-112D cell lines by two-dimensional electrophoresis (see 
Figure 4 for spot review).
Selected TOV-112D spots with undetectable TOV-81D matching spots
Spots positions IPI Accession number Description
1 IPI00218914.1 Aldehyde dehydrogenase 1A1
2 IPI00304925.1 Heat shock 70 kDa protein
3 IPI00021033.1 Collagen alpha 1(III) chain precursor
4 IPI00299000.1 Proliferation-associated protein 2G4
5 IPI00027834.2 Heterogeneous nuclear ribonucleoprotein L
6 IPI00025366.1 Citrate synthase, mitochondrial precursor
7 IPI00027834.2 Heterogeneous nuclear ribonucleoprotein L
8 IPI00302925.1 T-complex protein 1, theta subunit
9 IPI00164305.1 Membrane associated protein SLP-2
10 IPI00414123.1 Collapsin response mediator protein 1 (CRMP-1)
11 IPI00300086.1 Nicotinate-nucleotide pyrophosphorylase
12 IPI00008552.2 Thioredoxin-like protein 2
13 IPI00221234.1 Antiquitin
14 IPI00219077.1 Leukotriene A-4 hydrolase
15 IPI00001661.1 Regulator of chromosome condensation (RCC1)
16 IPI00334587.1 Heterogeneous nuclear ribonucleoprotein A/B
17 IPI00021187.1 RuvB-like 1
18 IPI00163782.1 Far upstream element binding protein 1
19 IPI00007074.1 Tyrosyl-tRNA synthetase
20 IPI00375441.1 Far upstream element (FUSE) binding protein 1
21 IPI00218342.6 C-1-tetrahydrofolate synthase, cytoplasmic
22 IPI00411623.1 Enabled protein homolog (MENA) similar to Avena
23 IPI00218342.6 C-1-tetrahydrofolate synthase, cytoplasmic
24 IPI00001661.1 Regulator of chromosome condensation (RCC1)
25 IPI00012079.1 Eukaryotic translation initiation factor 4B
26 IPI00009960.4 Mitochondrial inner membrane protein (Mitofilin)
27 IPI00411623.1 Enabled protein homolog (MENA) similar to Avena
Selected TOV-81D spots with undetectable TOV-112D matching spots
28 IPI00022314.1 Superoxide dismutase mitochondrial precursor
29 IPI00018352.1 Ubiquitin carboxyl-terminal hydrolase isozyme L1
30 IPI00218694.1 Caldesmon
31 IPI00306959.5 Keratin, type II cytoskeletal 7 (Cytokeratin-7)
32 IPI00220709.3 Tropomyosin
33 IPI00171834.2 Keratin, type I cytoskeletal 19 (Cytokeratin 19)
34 IPI00418411.1 Keratin, type II cytoskeletal 8 (Cytokeratin 8)
35 IPI00333771.1 Caldesmon
36 IPI00007118.1 Endothelial plasminogen activator inhibitor) (PAI-1)
37 IPI00333771.1 Caldesmon
38 IPI00026663.1 Aldehyde dehydrogenase 6
39 IPI00008524.1 Poly(A)-binding protein 1 (PABP 1)
40 IPI00027341.1 Macrophage capping protein (Actin-regulatory protein CAP-G)
41 IPI00029111.1 Dihydropyrimidinase related protein-3
42 IPI00029111.1 Dihydropyrimidinase related protein-3
43 IPI00333771.1 Caldesmon
44 IPI00337495.1 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase (Lysine hydroxylase) 2
45 IPI00337495.1 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase (Lysine hydroxylase) 2
46 IPI00329536.1 Early endosome antigen 1 (Endosome-associated protein p162)
Selected spots differentially expressed with a minimum deregulation fold of 2.0
47 IPI00219018.1 Glyceraldehyde-3-phosphate dehydrogenase
48 IPI00218918.1 Annexin I
49 IPI00003865.1 Heat shock cognate 71 kDa protein
50 IPI00018352.1 Ubiquitin carboxyl-terminal hydrolase isozyme L1
51 IPI00010796.1 Protein disulfide isomerase precursor (PDI)
52 IPI00022314.1 Superoxide dismutase mitochondrial precursor
53 IPI00025252.1 Protein disulfide-isomerase A3 precursor (Disulfide isomerase ER-60)
54 IPI00027350.1 Peroxiredoxin 2 (Thioredoxin-dependent peroxide reductase 1)
55 IPI00015262.5 Calponin H2
56 IPI00218694.1 Caldesmon
57 IPI00000877.1 150 kDa oxygen-regulated protein precursorProteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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Specific expression of protein isoforms
Another interesting feature that can be underscored from
the iTRAQ analysis is the importance of specific protein
isoforms that characterized each cell lines. For example,
the aldehyde dehydrogenase family 1 member A1
(ALDH1A1) is robustly overexpressed in TOV-112D com-
pared to TOV-81D but the ALDH1A3 isoform expression
is strongly repressed. ALDH1A1 and ALDH1A3 genes are
closely related but distinct members of the aldehyde dehy-
drogenase genes superfamily which are important
enzymes involved in the oxidative stress response and
detoxification processes with a general expression increase
in several tumours [42]. The same observation is applica-
ble to type-III and type-I collagen precursors that are
respectively overexpressed and underexpressed in TOV-
112D cells when compared to TOV-81D cells. Indeed,
type-III collagen has been suggested to play a role in breast
cancer [43] and serous ovarian carcinoma [44]. There is
also comparable discrepancy between annexin A1 and
annexin A2, two related proteins with possible roles into
membrane dynamics, cell differentiation and migration
[45] that are characterized with highly divergent
TOV112D:TOV81D expression ratios.
Differential protein expression analysis between TOV-81D 
and TOV-112D cell lines by two-dimensional 
electrophoresis
In contrast to LC-based quantitative proteomics such as
iTRAQ analysis, the gel-based two-dimensional electro-
phoresis is still very laborious although major technical
improvements have been developed over recent years.
2DE is a powerful tool for comparative protein expression
with complementary features over LC-based proteomics
with meaningful contribution to the understanding of cell
adaptation to tumour environment. The strength of 2DE
lies in the direct visualisation of post-translational altera-
tions that are reflected by changes in spot localizations.
A reliable comparative proteome analysis using 2DE-
based analysis requires the use of replicate groups to over-
come the inherent experimental variations that precluded
the obtention of reproducible and quantitative datasets.
Replicate group analysis ensures that consistent coordi-
nates are acquired for every detected spots and make pos-
sible statistical analysis of the data (Figure 3). This
approach resulted in the identification of several spots
that differ consistently between the two cell lines. A selec-
tion of manually reviewed spots localized in well focused
area of the gel that unambiguously meet both a two-fold
expression threshold and a Student's parametric test
assuming a normal distribution for small samples is pre-
sented in Figure 4 and the corresponding Table 2. In gen-
eral, the correlation of protein expression dataset from
2DE follows the same trend as the one generated by
iTRAQ analysis. For example, spots corresponding to col-
lagen alpha (Spot #3) and aldehyde dehydrogenase
(Spot#1) are unequivocally hallmarks of TOV-112D over-
expressed proteins to which strong iTRAQ ratios were also
determined. Inversely, very low iTRAQ protein ratios that
indicate a dramatic decrease of TOV-112D protein expres-
sion compared to TOV-81D have been calculated for pro-
teins such as prolyl 4-hydroxylase alpha-1 subunit
precursor (Spot#60), procollagen-lysine, 2-oxoglutarate
5-dioxygenase (Spot#44–45), plasminogen activator
inhibitor-1 precursor (Spot#36) or tropomyosin
(Spot#32). All of these proteins were identified by 2DE to
be overexpressed in TOV-81D. Together, the iTRAQ and
2DE datasets add confidence and credibility to the differ-
ential proteome analysis but the two methods are clearly
Representative 2DE gel image visualized by Sypro Ruby stain- ing Figure 3
Representative 2DE gel image visualized by Sypro Ruby stain-
ing. 250 µg of each protein extract was loaded on an immobi-
lised pH gradient strip (pH 3–10 non linear) followed by a 10 
% SDS-PAGE. Spots corresponding to LC MS/MS identified 
proteins are numbered from differentially expressed proteins 
between TOV-112D and TOV-81D as given by Gaussian 
modeling with the PDQuest ™ software (referenced from 
Table 2).
58 IPI00024911.1 Endoplasmic reticulum protein ERp29 precursor
59 IPI00021187.1 RUVB-like 1
60 IPI00218682.1 Prolyl 4-hydroxylase alpha-1 subunit precursor
61 IPI00007765.2 Stress-70 protein, mitochondrial precursor
62 IPI00219005.1 FK506-binding protein 4
63 IPI00216953.1 Lamin A/C
64 IPI00298363.2 Far upstream element binding protein 2
65 IPI00217056.1 Leprecan-like 2 protein
Table 2: Comparative protein expression analysis of TOV-81D and TOV-112D cell lines by two-dimensional electrophoresis (see 
Figure 4 for spot review). (Continued)Proteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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complementary since the two datasets do not completely
overlap. The identification of several 2DE spots with
intense overexpression as heat shock 70-kDa protein
(Spot#2) without equivalent iTRAQ ratios illustrate this
complementarity that could be explained by the different
physico-chemical processing of the samples or different
peptide representation between the two methods [11].
In addition to these observations, the present 2DE analy-
sis underscores the modification of protein expression rel-
ative to redox regulation and detoxification pathways.
Aldehyde dehydrogenase (Spot#1), a determinant protein
in resistance to multiple chemotherapeutic agents
through the inactivation of drugs into non cytotoxic
metabolites is tremendously overexpressed in TOV-112D.
However, proteins that are associated with the redox level
of the cell such as superoxide dismutase (Spot#28), pro-
tein disulfide isomerase (PDI) (Spot#51) or peroxire-
doxin (Spot#54) are generally found with more modest
expression compared to TOV-81D. The adaptation of
TOV-112D cells to hypoxia which was acquired from
selection of transformed cells resistant to oxygen depriva-
tion could explain that the expression of some proteins
involved in the detoxification of oxygen reactive species.
The adaptation of tumour cells to hypoxia and acidifica-
tion of the environment is also known to promote sur-
vival over normal cells. When tumour cells face stressful
conditions such as oxygen deprivation, the accumulation
of misfolded proteins can induce the expression of chap-
erones and heat shock proteins, a family of overexpressed
proteins systematically found in 2DE proteome analysis
of ovarian cancer cells. Changes such as the overexpres-
sion of chaperones and hypoxia-related proteins may
impact on the cellular behaviour of the TOV-112D cell
line which is characterized by high proliferative index.
Recent advances in two-dimensional electrophoresis have
greatly improved the reproducibility and analytical power
of the technique but still suffer from several important
limitations. The detection of low abundant spots and the
unambiguous annotation of a quantitative change in a
spot from which multiple protein identifications were
made (protein co-migration) are still common issues. The
protein dataset generated by the 2DE analysis is generally
limited to high abundant proteins in contrast to the
iTRAQ analysis that shows a wider panel of protein. How-
ever, 2DE remains a powerful technique to analyze differ-
ential protein expression because of its resolution of
complex proteomes. Moreover, 2DE is a method of choice
to indicate putative posttranslational modifications and
protein isoforms. For example, the multiple high molecu-
lar weight proteins in a typical pearl necklace pattern iden-
tified as isoforms of collagen alpha (Spot#3) proteins
suggests that this protein might be modified, presumably
by glycosylation, a modification that can affect the cells'
ability to adhere, migrate, and invade toward extracellular
matrix components [46]. Interestingly, the collagen alpha
gene has also been shown to be stimulated in hypoxia
Zoomed sections from TOV-112D and TOV-81D gels dem- onstrating differential expression of proteins listed in Table 2 Figure 4
Zoomed sections from TOV-112D and TOV-81D gels dem-
onstrating differential expression of proteins listed in Table 2. 
(A) Selected TOV-112D spots with undetectable TOV-81D 
matching spots. (B) Selected TOV-81D spots with undetecta-
ble TOV-112D matching spots. (C) Selected spots differen-
tially expressed with a minimum deregulation ratio of 2.0.Proteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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conditions [47], a physiological state likely relevant for
TOV-112D cells.
Validation of protein expression levels by immunological 
comparison of differentially expressed proteins identified 
by iTRAQ and 2DE analysis
The deregulation of some protein candidates identified by
iTRAQ or 2DE analysis has been validated by comparison
with quantitative immunoblots. Western blot analysis has
been performed to quantify protein expression of some
target proteins. The quantitative Western blot analysis
shown on Figure 5 for selected proteins follows the same
deregulation trend as noticed with 2DE or iTRAQ analysis.
Highly underexpressed proteins such as transgelin 2 are
clearly validated by Western blot since there is a pro-
nounced difference in signal intensity between the two
cell lines. The statistical analysis of Western blot is consist-
ent with 2DE and iTRAQ ratios evaluations. Converging
data from 2DE, iTRAQ and Western blot analysis add fur-
ther consistency and validation to our results.
Conclusion
Understanding the mechanisms underlying EOC have
been limited because little is known about the events of
neoplastic transformation, mechanisms of invasion and
metastatic dissemination. High-throughput differential
protein expression analysis like the present study is aimed
at the identification of those proteins that could collec-
tively add valuable information. The proteome analysis
presented here will be of use to the ovarian community to
help discriminate candidates of interest. The rapid devel-
opment of proteomics-based and protein microarray tech-
nologies brings new perspectives, such as systems biology,
to make an integrative approach of both technologies and
to ultimately give a global view of the cell behavior by
monitoring interaction networks. By taking into account
pathways, networks and mechanisms which all could
dynamically be linked together, systems biology will
broaden our view of the biological deregulations associ-
ated with cancer progression. The establishment of a rep-
ertoire of genes and proteins potentially involved in the
cell's transition to transformed phenotype is the prerequi-
Western blot validation of selected proteins identified by iTRAQ and/or 2DE analysis Figure 5
Western blot validation of selected proteins identified by iTRAQ and/or 2DE analysis. Equal amounts, 25 µg, of protein 
extracts from TOV-112D and TOV-81D cell lines were loaded onto a 12 % SDS-PAGE and processed for Western blotting 
with the indicated antibodies. Protein expression differences were quantified using a Chemilmager 4000 imaging system and 
AlphaEase software 3.3 (Alpha Innotech Corporation). The data are expressed as relative integrated density value (IDV). Each 
point represents the mean +/- SE from three independent experiments. Data were analysed by Student's unpaired t test. Rep-
resentative blots for each analysis are depicted.Proteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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site to conceptualize ovarian cancer with an all-inclusive
view.
Methods
Cell culture
Immortalized malignant epithelial ovarian tumour cell
line TOV-112D and low malignancy TOV-81D cell lines
were cultured (air/CO2, 19:1, 37°C) in medium consist-
ing of 50:50 (v:v) medium 199: medium 105 (Sigma),
supplemented with 10% foetal bovine serum (Hyclone).
Penicillin (100 U/ml) and streptomycin (100 mg/ml)
(Wisent) were added to culture media. When growth of
cells reached approximately 75–80% confluency, cells
were detached from the cell culture dishes using a Hanks
Balanced Salt Solution containing 0.05% trypsin and 0.53
mM EDTA (Wisent). Cell pellets were washed with low
salt PBS buffer (171 mM NaCl, 3.3 mM KCl,10 mM
Na2PO4, 2 mM NaH2PO4) and stored at -80°C.
Digestion and iTRAQ Labeling
100 µg of protein from each cell line was resuspended in
0.5 M triethyl ammonium bicarbonate (TEAB), and then
reduced, alkylated, digested and labeled according to the
standard protocol supplied by the manufacturer (Applied
Biosystems iTRAQ™ Reagents – Chemistry Reference
Guide, P/N 4351918A). iTRAQ results were generated
from the analysis of three isobaric tags combinations. For
the first combination, one sample from cell line TOV81D
and one from cell line TOV112D were labeled with iTRAQ
reagent 115 and 117, respectively. In a second analysis
where two combinations were selected, two samples from
each cell line were labeled. TOV81D was labeled with
iTRAQ reagents 114 and 116, while TOV112D was
labeled with iTRAQ reagents 115 and 117. Each cell line
was therefore analyzed in triplicates and three ratios
TOV112D/TOV81D were calculated (117/115 for analysis
1; 115/114 and 117/116 for analysis 2).
Fractionation of tryptic peptides
Strong Cation Exchange (SCX) Fractionation
For the first and second experiments, tryptic peptides were
fractionated using strong cation exchange (SCX) as fol-
low. Combined labeled samples were brought up to 2 mL
with buffer A (10 mM KH2PO4, pH 2.7, 25% ACN) and
injected onto a Polysulfoethyl A, 5 µm, 300 Å, 4.6 mm id
× 100 mm SCX column (Poly LC, Columbia, MD). Using
a Vision Workstation (Applied Biosystems, Foster City,
CA), the column was allowed to equilibrate for 20 min-
utes in buffer A before a gradient was applied: 0–35% B
(10 mM KH2PO4, pH 2.7, 25% ACN, 500 mM KCl) in 30
minutes at a flow rate of 0.5 ml/min. Fractions were col-
lected every minute after injection. For the LC-MS/MS
analysis, the fractions are selected based on the UV elution
profile, recorded at 215 nm. The selected fractions were
then reduced in volume, to about 180 µL, in a Speed-Vac
(Savant Instruments, Holbrook, NY) and transferred to
autosampler vials (LC Packings, Amsterdam).
Fractionation of tryptic peptides by isoelectric focusing (IEF) on 
immobilized pH gradient
For the third experiment, separation of tryptic peptides
according to their isoelectric point was used as a mean to
obtain better protein coverage and more accurate quanti-
tation for proteins that were identified with only one pep-
tide by the two first analyses. Labeled peptides were
lyophilized and resuspended in 315 µl of Milli-Q water
containing 0.2 % carrier ampholytes (Bio-Lyte 3/10, Bio-
Rad Laboratories). The resulting solution was used to
rehydrate an 18-cm immobilized pH gradient gel strip
(pH 5–8) for 10 hours at room temperature without any
voltage applied. Peptides were focused by applying a volt-
age of 250V for 15 minutes, then 10 000V for 3 hours and
finally 10 000 V for a total of 60 000 V•hour. Immediately
after focusing, the strip was cut into 36 segments of 5mm.
Gel pieces were transferred into a 96-well plate and pep-
tides were eluted by first incubating the gel pieces for 15
minutes in 2% acetonitrile, 0.5% formic acid and then for
15 minutes in 50% acetonitrile, 0.5% formic acid. The
extracted peptides were lyophilized using a SpeedVac and
resuspended in 25 µl of 0.1% formic acid in water. 5 µl of
this solution was used for LC-MS/MS analysis on a Q-TOF
mass spectrometer (QSTAR-XL, Applied Biosystems) as
described above.
LC-MS/MS analysis
Since the iTRAQ experiments were performed in two dif-
ferent proteomic facilities, the LC-MS/MS analyses were
slightly different. For the first and second iTRAQ experi-
ments, LC-MS/MS analysis was performed using an inte-
grated Famos autosampler, SwitchosII switching pump,
and UltiMate micro pump (LC Packings, Amsterdam) sys-
tem with an Hybrid Quadrupole-TOF LC/MS/MS Mass
Spectrometer (QSTAR Pulsar i, MDS Sciex, Concord,
Ontario, Canada) equipped with a nano-electrospray ion-
ization source (Proxeon, Odense, Denmark) and fitted
with a 10-µm-ID fused-silica emitter tip (New Objective,
Woburn, MA). About 25% of each fractions (40–50 µL)
was injected onto a 300 µm id × 5 mm C18 PepMap guard
column (5 µm, 100 Å, LC Packings, Amsterdam) and
washed for 10 minutes with 95 % solvent A (water/ACN
98:2 (v/v), 0.05% FA) and 5 % solvent B (water/ACN 2:98
(v/v), 0.05% FA) at a flow rate of 100 µL/min. Chromato-
graphic separation was achieved on a 75 µm id × 15 cm
C18 PepMap Nano LC column (3 µm, 100 Å, LC Packings,
Amsterdam) with a linear gradient from 5–60% solvent B
in 40 minutes, at 200 nL/min. If the observed UV absorb-
ance was greater than 0.1 for any fraction collected during
the SCX, a 2-hours gradient was used to compensate for
the larger amount of peptides in the fraction. MS data was
acquired automatically using Analyst QS 1.0 softwareProteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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Service Pack 8 (MDS SCIEX, Concord, Ontario Canada).
An information dependant acquisition (IDA) method,
consisting of a 1 second TOFMS survey scan of mass range
400–1200 amu and two 2.5 second product ion scans of
mass range 100–1500 amu, was used to fragment the two
most intense peaks, above 20 counts, with charge state 2
to 5. Once an ion was selected for MS/MS fragmentation,
it was put on an exclusion list for 180 seconds. A 6 amu
window was used to prevent the peaks from the same iso-
topic cluster from being fragmented again.
For the third iTRAQ experiment, LC-MS/MS analysis was
performed using the same LC system as described above
coupled with a QSTAR xl mass spectrometer equipped
with a nano-electrospray ionization source (MDS Sciex). 5
µl of each IEF fraction was injected, and peptides were
trapped on a 300 µm ID × 5 mm C18 PepMap guard col-
umn (LC Packings) using a solution of 0.1% FA in water
flowing at 15 µL/min. The peptide mixture was then sep-
arated on a 75 Am ID × 10 cm BioBasic C18 column (New
Objective) at a flow rate of 200 nL/min. The chromato-
graphic separation started at 98% buffer A (0.1% FA in
water) and 2% buffer B (0.1% FA in acetonitrile) for 5
minutes. The gradient was then performed as follow: 2%
to 25% B in 85 minute, 25% to 40% B in 10 min and 40%
to 80% B in 5 min. Eluted peptides were electrosprayed
through a 15-µm-ID fused-silica emitter tip (New objec-
tive) with an ion spray voltage of 2800 V. MS data was
acquired automatically using Analyst QS 1.1 software
(MDS SCIEX). An IDA method, consisting of a 1-second
TOFMS survey scan of mass range 400–1600 amu and
three 3-second product ion scans of mass range 100–2000
amu, was used to fragment the three most intense peaks,
above 15 counts, with charge state 2 to 4. Fragmented tar-
get ions were dynamically excluded for 60 seconds with a
100 ppm mass tolerance.
Data Analysis
Data files were processed using the ProQUANT software
(version 1.0, Applied Biosystems, Foster City, CA) in Ana-
lyst using the IPI Human database (version 3.05, EBI) and
the following parameters for searching. The MS and MS/
MS tolerances were set to 0.20 Da, which take into
account mass shift due to temperature variations. A tryptic
digestion always precedes labelling with iTRAQ reagents
and, therefore, ProQUANT always assumes the cleavage
sites are lysine and arginine, and one missed cleavage was
allowed. Methyl methanethiosulphonate (MMTS) modi-
fication of cysteines was used as a fixed modification. No
variable modification or amino acids substitution were
allowed. A threshold of 90 was set for peptide confidence.
In order to reduce protein redundancy, ProGroup viewer
(version 1.0.6, Applied Biosystems, Foster City, CA) was
used to assemble and report the data.
For each peptide identification, ProQUANT computes the
areas under the peaks at 114, 115, 116 and 117 Da, corre-
sponding to the four iTRAQ reagents. A user-define
denominator is used to calculate ratios (e.g. 115 was cho-
sen as the denominator for the first analysis). A statistical
determination of a significant over- or underexpression
threshold has been performed on the iTRAQ dataset using
the Statgraphics Centurion's (version 15.1.03, StatPoint,
Herndon, VA), Generalized Logistic distribution to the
ratios (TOV112D/TOV81D) for all the identified proteins.
The proteins identified from each iTRAQ analysis were
combined in a single table [see Additional file-1]. Average
ratio (geometrical mean) and relative standard deviation
(RSD) were calculated for each protein. Proteins with
ratios above 2.5 and under 0.59 were then extracted from
the list and manually validated. For higher protein identi-
fication and ratio confidence, only proteins with two, or
more, validated unique peptides were conserved [see
Additional file-2].
Mapping of the predominant biological processes of the
differentially expressed proteins on the GO hierarchy was
performed using BiNGO v1.0 [48] coupled to the visuali-
zation capacities of Cytoscape v2.4 [49]. GO annotations
p-values were obtained by hypergeometric satistical test
(cluster versus the whole annotation bank) and corrected
using Benjamin and Hochberg False Discovery Rate
included in the BiNGO software. GO database was
obtained as of July 1st, 2007. Gominer [50] analysis reveal
proteins distributions within selected GO categories.
Protein extraction and sample preparation for two-
dimensional gel electrophoresis
Cell pellets were resuspended in 2 ml of lysis buffer con-
taining 50 mM Tris-HCl pH 8.0, 1 mM MgCl2, 0.1% Tri-
ton X-100 (Sigma), 250 U of Benzonase™ (Novagen)
endonucleases (DNAse and RNAse) and Complete™ pro-
tease-inhibitor cocktail (according to Roche Diagnostics
instructions). The cell extract was mixed for 5 minutes to
achieve complete cell disruption and protein solubiliza-
tion, and incubated for 30 minutes at 37°C to facilitate
DNA and RNA degradation by the added endonucleases.
The volume was adjusted to 3 ml with lysis buffer and the
cell extract was mixed for another 5 minutes. Nine ml of
ice-cold acetone (3 volumes) were added and the extract
was kept at -30°C for 2 hours. The precipitate was centri-
fuged at 15000 × g for 15 minutes and the resulting pro-
tein pellet was washed twice with 10 ml of ice-cold
acetone. The pellet was air-dried and resuspended in the
Ready Prep-3™ 2D buffer (Bio-Rad) containing: 5 M urea,
2 M thiourea, 2% CHAPS, 2% SB 3–10, 40 mM Tris, 0.2%
Bio-Lytes 3–10. Protein concentration was estimated with
Bradford's protein assay (Bio-Rad).Proteome Science 2007, 5:16 http://www.proteomesci.com/content/5/1/16
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2DE proteome analysis
350 µl of 2D buffer containing 250 µg of each protein
sample were used for the rehydration of 18 cm immobi-
lized non-linear pH 3–10 gradient (IPG) strips (Amer-
sham Biosciences). A multi step IEF voltage program was
applied to the strips on a Protean IEF cell (Bio-Rad): 50 V
for 12 hours, 250 V for 15 minutes, 1000 V for 1 hour,
from 1000 V to 8000 V in a 5 hours step and a final step
of 60 000 V-hr at 8000 V. Strips were first reduced by incu-
bation in the equilibration/reduction buffer (6 M Urea,
0.375 M Tris pH 8.8, 2% SDS, 20% glycerol, 2% (w/v)
DTT (Sigma)) and then alkylated in the same buffer but
containing 2.5% (w/v) iodoacetamide (Sigma) instead of
DTT. The second dimension was accomplished by run-
ning the strips on 1.5 mm-thick SDS/10%-(w/v)-polyacr-
ylamide gels using the Protean II XL Multi-Cell (Bio-Rad).
The electrophoresis unit was cooled at 20°C with a water
circulation system and 40 mA/gel constant amperage was
applied to the system. Gels were stained for 18 hours with
SYPRO Ruby protein stain (Bio-Rad) according to manu-
facturer's instructions.
2DE Image analysis
Image acquisition was made using the CCD-based multi-
wavelength fluoro-imager PROXPress™ proteomic imag-
ing system (Perkin Elmer) at 100 µm resolution. A flat
field fluorescence correction was applied for SYPRO Ruby
fluorescence specifications: excitation and emission filters
respectively at 480/30 and 620/30 nm. Image analysis and
spot detection was accomplished with PDQuest™ 2-D
analysis software version 7.3 (Bio-Rad) using Gaussian
spot modeling. For quantitative spot comparison across
gels, matchsets of three replicates of TOV-81D and TOV-
112D 2D-gels were created. Automated and manual spot
matching has been performed. An analysis set of proteins
have been created to identify spots that are statistically sig-
nificant. This analysis set of differentially expressed pro-
teins is composed of spots unique to TOV-81D or TOV-
112D and protein spots shared by the two replicate
groups with a quantity variation threshold of 2.0. Repli-
cate groups of TOV-81D and TOV-112D allowed the esti-
mate of average quantities of their protein spots. Student's
t-test statistical analysis with 95% significance level has
been applied to the replicate groups. 155 proteins that
match the threshold and statistical analysis criteria were
selected for automated in-gel excision using a Spot Cutter
system (Bio-Rad).
Immunoblotting
For immunoblotting, cells were washed with ice-cold
phosphate-buffered saline and lysed in 1X lysis buffer
containing 50 mM Tris-HCl pH 8.0, 1 mM MgCl2, 0.1%
Triton X-100 (Sigma), 250 U of Benzonase™ (Novagen,
San Diego, CA) endonucleases (DNAse and RNAse) and
Complete™ protease-inhibitor cocktail (according to
Roche Diagnostics instructions). The cell extracts were
mixed for 5 minutes to achieve complete cell disruption
and protein solubilization, and incubated for 30 minutes
at 37°C to facilitate DNA and RNA degradation by the
added endonucleases. The protein lysates were centri-
fuged at 15000 g for 5 minutes and the protein concentra-
tion in the supernatant was estimated with Bradford's
protein assay (Bio-Rad, Missisauga, Canada). Protein
extracts (25 µg) were separated on SDS-PAGE and then
transferred onto a PVDF membrane (Millipore, Bedford,
MA). After incubating 1 hour with blocking solution
(PBS-T containing 5% non-fat milk), the membrane was
probed overnight, at room temperature with shaking, by
primary antibodies to Annexin 1, rabbit polyclonal anti-
body (1:10 000) (Zymed Laboratories, South San Fran-
cisco, CA); Hsp-70, mouse monoclonal antibody
(1:5000) and TCP-1α, mouse monoclonal antibody
(1:1000) (Calbiochem, San Diego, CA); Ebp1, rabbit pol-
yclonal antibody (1:5000) (Oncogene Research Products,
San Diego, CA); Transgelin (SM22α), rabbit polyclonal
antibody (1:10 000) (Abcam, Cambridge, MA) and nucle-
olin, mouse monoclonal antibody (1:2000) (Upstate Cell
Signaling, Lake Placid, NY). After washing with PBS-T,
species-specific horseradish peroxidase-conjugated sec-
ondary antibody was added for 1 hour at room tempera-
ture. Signals were detected with Western Lightning™
Chemiluminescence reagent plus kit (Perkin Elmer, Bos-
ton, MA).
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